Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Translational Research Training Program in Addiction, City College of New York, New York, New York.
Am J Addict. 2020 Jan;29(1):51-56. doi: 10.1111/ajad.12979. Epub 2019 Nov 29.
This retrospective analysis of data from heroin users screening for clinical research, sought to determine if more naloxone is needed to precipitate opioid withdrawal among those who regularly use heroin with fentanyl, as opposed to those who use heroin without fentanyl.
Over the course of three to five screening visits, participants completed assessments of drug use, along with urine toxicology tests at each visit. To test for opioid dependence, 29 participants completed a modified Wang test (score: 0-150) during which an intramuscular dose of naloxone (0.2-0.4 mg) was administered and the severity of withdrawal was quantified.
The severity of opioid withdrawal was compared between individuals whose urine toxicology regularly tested positive for fentanyl (N = 15), and those only positive for other opioids (N = 14). No significant differences were found in demographic or drug use between the fentanyl-positive (mean: age 41.1 years, 9.1 bags heroin/d) and fentanyl-negative (42.0 years, 10.0 bags heroin/d) groups. Intramuscular naloxone-precipitated robust withdrawal in both samples (P < .01) with no significant difference (P = .8) in the severity (fentanyl positive [100.6 ± 13.4]; fentanyl negative [82.7 ± 9.6]).
These data suggest that a standard naloxone dose can be equally effective at precipitating withdrawal in individuals using heroin with fentanyl compared to heroin without fentanyl. These data contribute to our understanding of how naloxone antagonizes the effects of fentanyl and may have significant implications for the clinical laboratory and opioid overdose. A prospective clinical laboratory study with the proper opioid maintenance controls is needed to provide a more definitive finding. (Am J Addict 2019;00:00-00).
本研究通过对海洛因使用者进行临床研究筛查的数据进行回顾性分析,旨在确定与仅使用海洛因者相比,经常使用含芬太尼海洛因者需要更多的纳洛酮来诱发阿片类药物戒断。
在三到五次的筛查访视中,参与者完成了药物使用评估,并在每次访视时进行尿液毒理学测试。为了测试阿片类药物依赖,29 名参与者在经过改良的 Wang 测试(评分:0-150)期间接受了肌肉内纳洛酮(0.2-0.4mg)剂量,量化了戒断的严重程度。
将尿液毒理学定期检测到芬太尼阳性(N=15)的个体与仅检测到其他阿片类药物阳性(N=14)的个体的阿片类药物戒断严重程度进行比较。芬太尼阳性组(平均年龄 41.1 岁,9.1 袋海洛因/天)和芬太尼阴性组(42.0 岁,10.0 袋海洛因/天)在人口统计学和药物使用方面无显著差异。两种样本中肌肉内纳洛酮诱发的戒断均很明显(P<.01),严重程度无显著差异(P=.8)(芬太尼阳性[100.6±13.4];芬太尼阴性[82.7±9.6])。
这些数据表明,标准纳洛酮剂量在诱发使用含芬太尼海洛因的个体戒断方面与不使用芬太尼的海洛因个体同样有效。这些数据有助于我们了解纳洛酮如何拮抗芬太尼的作用,可能对临床实验室和阿片类药物过量具有重要意义。需要进行前瞻性临床实验室研究,以提供更明确的发现,并设置适当的阿片类药物维持对照。